Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
French drugmaker Sanofi SA terminated a partnership with Lexicon Pharmaceuticals Inc. to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.
The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.
Abbott Laboratories plans to ramp up manufacturing capacity for the company’s lower-cost continuous glucose monitor – the FreeStyle Libre – by three to five times in the next few years, aiming to reach millions more patients worldwide.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.
A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.
The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.
Obese people who engaged in resistance training were more likely to see reductions in a type of heart fat, a new study finds.
Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.
